CA2432792C - Procedes relatifs a la modulation de la croissance tumorale et de la metastase - Google Patents

Procedes relatifs a la modulation de la croissance tumorale et de la metastase Download PDF

Info

Publication number
CA2432792C
CA2432792C CA2432792A CA2432792A CA2432792C CA 2432792 C CA2432792 C CA 2432792C CA 2432792 A CA2432792 A CA 2432792A CA 2432792 A CA2432792 A CA 2432792A CA 2432792 C CA2432792 C CA 2432792C
Authority
CA
Canada
Prior art keywords
combretastatin
compound
tumor
administration
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2432792A
Other languages
English (en)
Other versions
CA2432792A1 (fr
Inventor
Francis Y. Lee
Ronald Peck
David Chaplin
Ronald Pero
Klaus Edvardsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Mateon Therapeutics Inc
Original Assignee
Bristol Myers Squibb Co
Oxi Gene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Oxi Gene Inc filed Critical Bristol Myers Squibb Co
Publication of CA2432792A1 publication Critical patent/CA2432792A1/fr
Application granted granted Critical
Publication of CA2432792C publication Critical patent/CA2432792C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des procédés et des compositions pharmaceutiques pour la modulation de la croissance tumorale ou de la métastase.
CA2432792A 2000-12-22 2001-12-20 Procedes relatifs a la modulation de la croissance tumorale et de la metastase Expired - Fee Related CA2432792C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25819500P 2000-12-22 2000-12-22
US60/258,195 2000-12-22
PCT/US2001/050261 WO2002056692A1 (fr) 2000-12-22 2001-12-20 Procedes relatifs a la modulation de la croissance tumorale et de la metastase

Publications (2)

Publication Number Publication Date
CA2432792A1 CA2432792A1 (fr) 2002-07-25
CA2432792C true CA2432792C (fr) 2012-04-03

Family

ID=22979500

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2432792A Expired - Fee Related CA2432792C (fr) 2000-12-22 2001-12-20 Procedes relatifs a la modulation de la croissance tumorale et de la metastase

Country Status (5)

Country Link
EP (1) EP1351573A4 (fr)
JP (2) JP2004523517A (fr)
AU (1) AU2002246827B2 (fr)
CA (1) CA2432792C (fr)
WO (1) WO2002056692A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69931766T2 (de) 1998-04-03 2007-05-31 Ajinomoto Co., Inc. Antitumorale mittel
AU2002216029B2 (en) 2000-10-27 2006-01-05 Pfizer, Inc. A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
WO2002056692A1 (fr) * 2000-12-22 2002-07-25 Bristol-Myers Squibb Company Procedes relatifs a la modulation de la croissance tumorale et de la metastase
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
JP2006503852A (ja) * 2002-09-25 2006-02-02 ユニバーシティー オブ ロチェスター 抗癌薬としてのカスパーゼインヒビター
WO2004032947A1 (fr) * 2002-10-09 2004-04-22 Unibioscreen S.A. Extrait ayant un action antitumoral et antitoxique
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2047858A1 (fr) * 2007-10-10 2009-04-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Produits de combinaison pour le traitement contre le cancer
ES2529434T3 (es) * 2007-11-21 2015-02-20 Oxigene, Inc. Método para tratar neoplasias hematopoyéticas
US20090209496A1 (en) * 2008-02-15 2009-08-20 David Chaplin Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2939665B1 (fr) 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
JP2018523712A (ja) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
CN107773556B (zh) * 2016-08-26 2020-08-18 广州安好医药科技有限公司 一种具有抗肿瘤药物功效的联合用药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
CA1338645C (fr) 1987-01-06 1996-10-15 George R. Pettit Isolation, caracterisation structurelle et synthese de nouvelles substances antineoplastiques, appelees "combretastatines"
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
WO1999035150A1 (fr) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthese de promedicaments a base de combrestatine a-4 et de leurs trans-isomeres
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
US6538038B1 (en) 1999-02-18 2003-03-25 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
WO2002056692A1 (fr) * 2000-12-22 2002-07-25 Bristol-Myers Squibb Company Procedes relatifs a la modulation de la croissance tumorale et de la metastase

Also Published As

Publication number Publication date
JP2004523517A (ja) 2004-08-05
AU2002246827B2 (en) 2008-02-21
EP1351573A1 (fr) 2003-10-15
CA2432792A1 (fr) 2002-07-25
EP1351573A4 (fr) 2007-03-28
JP2009102350A (ja) 2009-05-14
WO2002056692A1 (fr) 2002-07-25

Similar Documents

Publication Publication Date Title
JP2009102350A (ja) 腫瘍増殖および転移を調節するための方法
US20090258937A1 (en) Methods for Modulating Tumor Growth and Metastasis
AU2002246827A1 (en) Methods for modulating tumor growth and metastasis
US20090209496A1 (en) Methods and compositions for enhancing the efficacy of rtk inhibitors
EP1173187B1 (fr) Preparations combinees renfermant des derives d'anthracycline et des derives de platine
EP1835898A2 (fr) Methode de modulation de la croissance tumorale et des metastases
US20040014694A1 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy
CZ302451B6 (cs) Protirakovinová farmaceutická kombinace
AU779922B2 (en) Formulations for parenteral use of estramustine phosphate and amino acids
KR20090130098A (ko) 이소포스포르아미드 머스타드의 염 및 이의 동족체
AU1583201A (en) Combination chemotherapy
JP2006528696A (ja) 抗癌剤の抗腫瘍活性を増強する方法
US6562834B2 (en) Combination comprising camptothecin and a stilbene derivative for the treatment of cancer
ZA200210285B (en) Use of estramustine phosphate in the treatment of bone metastasis.
AU2002216029A1 (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
US20110110940A1 (en) Methods for Enhancing the Efficacy of Vascular Disrupting Agents
AU2004248968A1 (en) Compositions comprising ZD6126 together with 5-FU, CPT-11 or 5-FU and CPT-11 having vascular damaging activity for treating e.g. colorectal cancer
US20040014729A1 (en) Use of estramustine phosphate in the treatment of bone metastasis

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20171220